Skip to main content
Clinical Trials/ITMCTR1900002503
ITMCTR1900002503
Not yet recruiting
未知

A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. Meet the 2010 European League Against Rheumatism and the American College of Rheumatology RA classification criteria and have a RA course of at least 6 weeks;
  • 2\. Aged 18\-65 years old;
  • 3\. AT least three swollen joints (SJC) and five tender joints (TJC);
  • 4\. Erythrocyte sedimentation rate (ESR)\>28mm/h or C\-reactive protein (CRP)\>20mg/L;
  • 5\. Sign the informed consent form.

Exclusion Criteria

  • 1\. pregnant or lactating women;
  • 2\. There are fertility requirements at present and in the future;
  • 3\. History of chronic severe infection, any current infection and any malignant tumor;
  • 4\. Patients with severe primary diseases and mental illnesses such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems;
  • 5\. Those with a history of drug allergy;
  • 6\. Using disease\-modifying anti\-rheumatic drugs (DMARDs) and biological disease\-modifying anti\-rheumatic drugs within the first 3 months of enrollment;
  • 7\. The investigator believes that it is not appropriate to participate in this clinical trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials